Greenhouse Funds LLLP Grows Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Greenhouse Funds LLLP boosted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 5.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,701,897 shares of the medical research company’s stock after acquiring an additional 237,491 shares during the period. NeoGenomics comprises 3.2% of Greenhouse Funds LLLP’s portfolio, making the stock its 17th largest holding. Greenhouse Funds LLLP owned approximately 3.66% of NeoGenomics worth $77,487,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Nordea Investment Management AB lifted its holdings in NeoGenomics by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock valued at $1,301,000 after purchasing an additional 2,125 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of NeoGenomics by 1.2% during the third quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock valued at $45,022,000 after buying an additional 36,136 shares during the period. Swiss National Bank grew its stake in NeoGenomics by 1.0% in the 4th quarter. Swiss National Bank now owns 252,100 shares of the medical research company’s stock worth $4,155,000 after acquiring an additional 2,600 shares during the period. Jennison Associates LLC boosted its holdings in shares of NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company’s stock worth $24,963,000 after purchasing an additional 238,288 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in NeoGenomics by 2.4% in the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company’s stock valued at $6,411,000 after purchasing an additional 9,098 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

NeoGenomics stock opened at $9.58 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The firm’s fifty day moving average price is $10.10 and its 200 day moving average price is $13.57. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -15.45 and a beta of 1.41. NeoGenomics, Inc. has a 12-month low of $8.05 and a 12-month high of $19.12.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. On average, research analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Ratings Changes

NEO has been the topic of several research analyst reports. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler dropped their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Bank of America reduced their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. The Goldman Sachs Group cut their price objective on NeoGenomics from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, April 17th. Finally, Needham & Company LLC decreased their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, NeoGenomics currently has an average rating of “Moderate Buy” and an average target price of $19.30.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.